Bevacizumab biosimilar is under clinical development by Zhejiang Teruisi Pharmaceutical and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bevacizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bevacizumab biosimilar overview
Bevacizumab biosimilar is under development for the treatment of colorectal cancer, non-small cell lung cancer and other tumor diseases. The drug candidate is recombinant humanized anti-VEGF monoclonal antibody injection. It is administered through intravenous route and acts by targeting human vascular endothelial growth factor (VEGF).
For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.